16:10 EDT Summit Therapeutics (SMMT) reports Q1 adjusted EPS (7c), consensus (7c)
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics options imply 6.7% move in share price post-earnings
- Is SMMT a Buy, Before Earnings?
- Summit Therapeutics selloff Friday on data overdone, says H.C. Wainwright
- Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials
- BMO says Keytruda ‘still reigns’ after ivonescimab survival data
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue